Nuvalent, Inc. is a Pharmaceuticals company based in the United States, focusing on developing targeted therapies for cancer patients. The company has a medium risk rating score of 27.3. Nuvalent's operations are centered around creating small molecules to improve existing therapies for kinase targets. Their product candidates, including NVL-520, NVL-655, and NVL-330, aim to address specific cancer types. With a focus on ESG principles, Nuvalent is dedicated to sustainable healthcare solutions.